Hanmi Pharm Resumes U.S. Sales of Osteoarthritis Injection 'Hyaluma'

Hyaluma, an osteoarthritis treatment injection by Hanmi Pharm (U.S. launch name 'SynoJoint')

[Asia Economy Reporter Chunhee Lee] Hanmi Pharmaceutical's osteoarthritis treatment injection 'Hyaluma' will resume sales in the United States starting this month. The company plans to expand its market presence by changing its local distributor to a company with strengths in the orthopedic field.

Hanmi Pharmaceutical announced on the 7th that it will partner with global medical device company Asrex to sell Hyaluma (marketed as 'SynoJoint' in the U.S.) nationwide. Asrex is a distributor with over 4,000 specialized personnel handling more than 13,000 medical device products and is recognized for its strong sales network in orthopedics.

The two companies plan to work closely to advance Hyaluma's entry into the U.S. market. Asrex will handle marketing, sales, and distribution, while Hanmi Pharmaceutical will produce finished products at its Pyeongtaek Bio Plant in Gyeonggi Province and supply them locally.

Hyaluma is a high-molecular hyaluronic acid product produced in-house by Hanmi Pharmaceutical using advanced fermentation engineering technology. It is an osteoarthritis treatment injection administered directly to joint areas. After completing Phase 3 clinical trials in the U.S. and an inspection of the Pyeongtaek Bio Plant, it received approval from the U.S. Food and Drug Administration (FDA) in 2018. Hanmi Pharmaceutical initially entered the U.S. market through a contract with Teva but reclaimed the sales rights from Teva to accelerate Hyaluma's market establishment and has now resumed sales in partnership with Asrex.

Woo Jong-soo, CEO of Hanmi Pharmaceutical, stated, "We will do our best to ensure Hyaluma grows into a successful product in the U.S. market by closely cooperating with a new partner who has a strong understanding of the U.S. market and a powerful local sales network."

This content was produced with the assistance of AI translation services.